Melek Tugce Yilmaz1, Melis Gultekin1, Suayib Yalcin2, Murat Tuncel3, Gokhan Gedikoglu4, Ferah Yildiz1, Mustafa Cengiz1. 1. Hacettepe University Faculty of Medicine, Department of Radiation Oncology, Ankara, Turkey. 2. Hacettepe University Faculty of Medicine, Department of Medical Oncology, Ankara, Turkey. 3. Hacettepe University Faculty of Medicine, Department of Nuclear Medicine, Ankara, Turkey. 4. Hacettepe University Faculty of Medicine, Department of Pathology, Ankara, Turkey.
Abstract
BACKGROUND: Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract. These tumors are rare and only make bone metastases at a rate of 5%. CASE SUMMARY: A 31-year-old male with a GIST presented with solitary bone metastasis at the right iliac bone. We performed stereotactic ablative radiotherapy (SABR) and achieved excellent local control. Herein, our case is presented, and a short review of the literature is carried out. CONCLUSION: SABR should be considered as a treatment option in GIST with bone metastasis.
BACKGROUND: Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract. These tumors are rare and only make bone metastases at a rate of 5%. CASE SUMMARY: A 31-year-old male with a GIST presented with solitary bone metastasis at the right iliac bone. We performed stereotactic ablative radiotherapy (SABR) and achieved excellent local control. Herein, our case is presented, and a short review of the literature is carried out. CONCLUSION: SABR should be considered as a treatment option in GIST with bone metastasis.
Authors: L Gatto; M Nannini; M Saponara; V Di Scioscio; G Beltramo; G P Frezza; G Ercolani; A D Pinna; A Astolfi; M Urbini; G Brandi; G Biasco; M A Pantaleo Journal: Clin Sarcoma Res Date: 2017-01-10
Authors: Pascal Bucher; Peter Villiger; Jean-François Egger; Leo H Buhler; Philippe Morel Journal: Swiss Med Wkly Date: 2004-03-20 Impact factor: 2.193
Authors: Heikki Joensuu; Mikael Eriksson; Juhani Collan; Marja H Balk; Serge Leyvraz; Michael Montemurro Journal: Radiother Oncol Date: 2015-07-27 Impact factor: 6.280